Separham Ahmad, Aslan-Abadi Naser, Sedigh Hamid, Javan-Ajdadi Reza, Mehravani Kazem
Cardiovascular Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Galen Med J. 2023 Dec 1;12:e3126. doi: 10.31661/gmj.v12i.3126. eCollection 2023.
The purpose of this study was to assess the prognostic value of the monocyte-to-high-density lipoprotein ratio (MHR) as a marker of inflammation in patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).
This retrospective cross-sectional study was conducted on patients with a diagnosis of STEMI who underwent PCI between March 2021 and March 2022 at Madani Training and Research Hospital in Tabriz, Iran. Data regarding clinical and demographic properties, and laboratory parameters were obtained from medical records. Patients were categorized into two groups according to the median of admission MHR.
The study population consisted of 652 patients, 378 males (58%), and 275 females (42%), with a median age of 68 years (interquartile range: 57-77). Results showed that groups with higher MHR (15.59) had higher rates of in-hospital mortality and higher major adverse cardiovascular events (MACEs) in comparison with the group featuring lower MHR (15.59). Receiver operating characteristic (ROC) curves demonstrated that MHR could predict in-hospital mortality with a 75.7% sensitivity and 53.5% specificity, as well as predict MACE with 60.2% sensitivity and 59.7% specificity. Multivariate analyses indicated that MHR is an independent predictor of both in-hospital mortality (OR 1.05, 95% CI 1.02-1.08, P=0.002) and MACE (OR 1.05, 95% CI 1.02-1.08, P0.001).
This research indicated that the rise in MHR was independently associated with a higher risk of MACE and in-hospital mortality in STEMI patients undergoing primary PCI.
本研究旨在评估单核细胞与高密度脂蛋白比值（MHR）作为炎症标志物对接受直接经皮冠状动脉介入治疗（PCI）的ST段抬高型心肌梗死（STEMI）患者的预后价值。
本回顾性横断面研究对2021年3月至2022年3月期间在伊朗大不里士的马达尼培训与研究医院接受PCI的STEMI患者进行。临床和人口统计学特征以及实验室参数数据均从病历中获取。根据入院时MHR的中位数将患者分为两组。
研究人群包括652例患者，其中男性378例（58%），女性275例（42%），中位年龄为68岁（四分位间距：57 - 77岁）。结果显示，与MHR较低（15.59）的组相比，MHR较高（15.59）的组院内死亡率和主要不良心血管事件（MACE）发生率更高。受试者工作特征（ROC）曲线表明，MHR预测院内死亡率的灵敏度为75.7%，特异度为53.5%，预测MACE的灵敏度为60.2%，特异度为59.7%。多因素分析表明，MHR是院内死亡率（OR 1.05，95%CI 1.02 - 1.08，P = 0.002）和MACE（OR 1.05，95%CI 1.02 - 1.08，P < 0.001）的独立预测因子。
本研究表明，MHR升高与接受直接PCI的STEMI患者发生MACE和院内死亡的较高风险独立相关。
